CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg +3 moredrug
Likely dose
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01037452
NCT01037452Phase 2Completed

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone

Novartis·interventional·Posted Dec 23, 2009·Updated Mar 28, 2011

In Brief

A Phase 2 clinical trial evaluating Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, and 2 other interventions for Heartburn. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This study will investigate the safety and efficacy of an antacid/Lansoprazole combination product for the relief of heartburn after consuming a heartburn-inducing meal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeartburn
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 23, 2009
Enrollment StartDec 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.5 years ago

Interventions

Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mgdrug

Tablet

Lansoprazoledrug

Tablet

Calcium carbonate/magnesium hydroxidedrug

Tablet

Placebodrug

Tablet